J. Paul Waymack, M.D., Sc.D. joined the Relief team in November 2020 as Development and Regulatory Consultant. He has an extensive track record in the pharmaceutical drug development arena and currently serves as President of Waymack Consulting, which provides expert services to healthcare companies. He was the founder of Kitov Pharmaceuticals and served as its Chairman of the Board of Directors as well as its Chief Medical Officer from the company's founding until his retirement in 2019. During his tenure, Kitov was granted U.S. FDA approval for its NDA for its first drug, Consensi™ (amlodipine plus celecoxib), for the simultaneous treatment of osteoarthritic pain and hypertension. Prior to founding Kitov, Paul was a U.S. FDA medical officer, an associate professor of surgery and director of the surgical intensive care unit at the New Jersey School of Medicine and Dentistry. He was also formerly chief of surgical studies at the U.S. Army’s Institute for Surgical Research. He has been granted multiple patents and has authored or co-authored over 100 publications. He currently sits on multiple boards of directors and advisory boards for companies within the pharmaceutical industry. He received his M.D. from the Virginia Commonwealth University School of Medicine.
Paul strengthens the management team in all activities pertaining to the late-stage development of all pipeline assets.